References
Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2015) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int
Brown JP, Roux C, Törring O et al (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res 28:746–752
Bone HG, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Dakin P, Wagman, Papapoulos S. Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension trial. Annual meeting of the American Society for Bone and Mineral Research (ASBMR), October 9–12, 2015, Seattle, USA
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
A.D. Anastasilakis has received lecture fees and research grants from Amgen and lecture fees from Bianex, Eli-Lilly, and ITF; P. Makras has received lecture fees and research grants from Amgen and lecture fees from Pfizer, Leo, Genesis, ELPEN, UniPharma, Bianex.
Rights and permissions
About this article
Cite this article
Anastasilakis, A.D., Makras, P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27, 1929–1930 (2016). https://doi.org/10.1007/s00198-015-3459-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-015-3459-5